ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
- 6 September 2022
- journal article
- research article
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 7 (11) , 1024-1035
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseasesDrug Discovery Today, 2021
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative ColitisGastroenterology, 2020
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2019
- Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled StudyAntimicrobial Agents and Chemotherapy, 2017
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2017
- Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)Journal of Gastroenterology, 2017
- Ozanimod Induction and Maintenance Treatment for Ulcerative ColitisNew England Journal of Medicine, 2016
- A Systematic Review of the Measurement of Endoscopic Healing in Ulcerative Colitis Clinical TrialsInflammatory Bowel Diseases, 2014
- Ulcerative colitisThe Lancet, 2012
- C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based studyGut, 2008